

Rec'd PTO 16 FEB 2006

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
RLL-299US

In Re Application Of: **BISWAS et al.**

10/533246

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/533,246	10/30/03	TBA	26815	TBA	TBA

Title:  
**AMORPHOUS MOXIFLOXACIN HYDROCHLORIDE**

Address to:  
**Commissioner for Patents**  
**P.O. Box 1450**  
**Alexandria, VA 22313-1450**

**37 CFR 1.97(b)**

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

**37 CFR 1.97(c)**

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:
- ☐ the statement specified in 37 CFR 1.97(e);
- OR**
- ☐ the fee set forth in 37 CFR 1.17(p).

Docket No.  
**RLL-299US**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/533,246	10/30/03	TBA	26815	TBA	TBA

### Payment of Fee

☐ A check in the amount of \_\_\_\_\_ is attached.

☒ The Director is hereby authorized to charge and credit Deposit Account No. 50-0912  
as described below.

☐ Charge the amount of \_\_\_\_\_

☐ Credit any overpayment.

☒ Charge any additional fee required.

☐ Payment by credit card. Form PTO-2038 is attached.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

**Certificate of Mailing by First Class Mail**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

(Date)

(Date)

**Signature**

**Signature of Person Mailing Correspondence**

***Typed or Printed Name of Person Signing Certificate***

***Typed or Printed Name of Person Mailing Certificate***

**\*This certificate may only be used if paying by deposit account.**

**Dated: 16 February 2006**

**William D. Hare**  
**Reg. No. 44,739**  
**Ranbaxy Inc.**  
**600 College Road East, Suite 2100**  
**Princeton, NJ 08540**  
**Tel.: (609) 720-5378**  
**Fax: (609) 514-9779**

CC:

**INFORMATION DISCLOSURE CITATION**

Docket No.: RL 9US

Serial No.: 10/533,246

Applicants: BISWAS *et al.*

Filed: 4/29/2005

Group:

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	4,990,517	2/5/1991	Petersen <i>et al.</i>	514	300	
	A2	5,607,942	3/4/1997	Petersen <i>et al.</i>	546	200	
	A3	5,849,752	12/15/1998	Grunenberg <i>et al.</i>	514	300	

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES   NO	

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

	C1	Konne, <i>Chem. Pharm. Bull.</i> , 38:2003 (1990)

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.